Jefferies Financial Group Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Jefferies Financial Group initiated coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating on the stock.

Other research analysts have also issued research reports about the company. Guggenheim started coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price for the company. Scotiabank began coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective on the stock. Bank of America decreased their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Finally, Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a report on Thursday, October 24th. They issued an “overweight” rating on the stock. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics has an average rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Stock Up 1.1 %

Shares of KROS opened at $67.91 on Tuesday. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00. The business’s 50 day simple moving average is $57.74 and its 200-day simple moving average is $52.10.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 45.13% and a negative net margin of 27,890.94%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.33) EPS. Research analysts predict that Keros Therapeutics will post -4.93 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 22.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. KBC Group NV increased its stake in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Keros Therapeutics in the second quarter valued at $128,000. Finally, Ameritas Investment Partners Inc. boosted its stake in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.